Abstract A series of pyrrolo [3, 2-d] pyrimidineone compounds have been designed and
synthesized as novel FXa inhibitors. Bioassay of the tested compounds showed moderate to …

A series of novel tetrahydropyrazolopyridone derivatives containing 1, 3, 4-triazole,
triazolylmethyl, and partially saturated heterocyclic moieties as P2 binding element was …

Firstly, a series of Isosteviol derivatives were synthesized and evaluated for FXa inhibitory
activity. Among these compounds, the inhibitory activity of compounds 22, 35 and 38 on FXa …

A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl) aminopyrrolidin-2-one-based
factor Xa (fXa) inhibitors, incorporating an alanylamide P4 group, was designed and …

Factor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become
a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been …

Factor Xa (FXa) is well known to play a pivotal role in blood coagulation, so FXa inhibitor is a
promising drug candidate for prophylaxis and treatment of thromboembolic diseases. In the …

Four series of novel and potent FXa inhibitors possessing the 1, 2, 4-triazole moiety and
pyrrole moiety as P2 binding element and dihydroimidazole/tetrahydropyrimidine groups as …

Direct inhibition of FXa has emerged as an effective strategy to achieve anticoagulation
maintaining normal hemostasis with minimal bleeding risks. A novel series of …

Coagulation factor Xa (fXa) is a particularly attractive target for the development of effective
and safe anticoagulants. In this study, novel 2, 3-dihydroquinazolin-4 (1H)-one derivatives …

Using N, N-dialkylated benzamidines as the novel P4 motifs, we have designed and
synthesized a class of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent and …